

Press Release

04 January 2024 08:30:00 CET

2cureX announces changes to the Board of Directors.

2cureX, a pioneer in the use of 3D tumoroids for predicting cancer treatment efficacy, is implementing significant changes in its governance resulting in four Board members leaving the Board of Directors.

The company is transitioning from a centralized model, where drug sensitivity testing is solely conducted in its Copenhagen laboratories, to a decentralized business model. This shift will enable IndiTreat testing at various hospitals throughout Europe and beyond.

Tonni Bülow-Nielsen, Chairman of the Board, explains, “This strategic evolution requires an adaptation in our Board of Directors and Management, introducing new expertise, connections, and insights that align with our evolving business approach.” He adds, “consequently, four Board members have chosen to depart. We are currently engaging with highly qualified individuals possessing extensive knowledge in Diagnostics and Medtech, aiming to significantly strengthen our Board in the near future.”

The exiting members, Povl-Andre’ Bendz, Camilla Huse Bondesson, Michael Schaeffer, and Michel Klimkeit, are concluding their lengthy service on the Board. Vice-Chairman and Founder Ole Thastrup expresses “deep appreciation for their contributions to 2cureX’s development”.

For more information about 2cureX:

Ole Thastrup, Vice-Chairman
E-mail: ot@2curex.com
Telephone: +45 2211 5399
www.2curex.com

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com

Certified Adviser: Redeye AB

Attachments

[2cureX announces changes to the Board of Directors.](#)